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ABSTRACT 
During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed 
hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain 
(RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that 
antibodies will be essential for protection. However, little is known about the human 
antibody response to SARS-CoV-21-5. Here we report on 68 COVID-19 convalescent 
individuals. Plasmas collected an average of 30 days after the onset of symptoms had variable 
half-maximal neutralizing titers ranging from undetectable in 18% to below 1:1000 in 78%, 
while only 3% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-
specific memory B cells expressing closely related antibodies in different individuals. Despite 
low plasma titers, antibodies to distinct epitopes on RBD neutralized at half-maximal 
inhibitory concentrations (IC50s) as low as few ng/mL. Thus, most convalescent plasmas 
obtained from individuals who recover from COVID-19 without hospitalization do not 
contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific 
antibodies with potent antiviral activity were found in all individuals tested, suggesting that 
a vaccine designed to elicit such antibodies could be broadly effective.   
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Between April 1 and April 17, 2020, 73 eligible participants enrolled in the study. Of these, 48 
(65.8%) were individuals diagnosed with SARS-CoV-2 infection by RT-PCR (cases), and 25 
(34.2%) were close contacts of individuals diagnosed with SARS-CoV-2 infection (contacts). 
While inclusion criteria allowed for enrollment of asymptomatic participants, 5 close contacts that 
did not develop symptoms were excluded from further analyses. The 68 cases and contacts were 
free of symptoms suggestive of COVID-19 for at least 14 days at the time of sample collection. 
Participant demographics and clinical characteristics are shown in Table 1 and Extended Data 
Tables 1 and 2. Only one individual who tested positive for SARS-CoV-2 infection by RT-PCR 
remained asymptomatic. The other 67 participants reported symptoms suggestive of COVID-19 
with an average onset of approximately 30 days (range 17 to 48 days) before sample collection. In 
this cohort, symptoms lasted for an average of 10 days (0-28 days), and none of the participants 
were hospitalized. The most common symptoms were fever (82.4%), cough (64.7%), myalgia 
(55.9%) and fatigue (54.4%) while baseline comorbidities were infrequent (8.8%) (Table 1 and 
Extended Data Tables 1 and 2). There were no significant differences in duration or severity of 
symptoms, or in time from onset of symptoms to sample collection between genders or between 
cases and contacts (Extended Data Figure 1). 
 
Plasma samples were tested for binding to the SARS-CoV-2 RBD and trimeric spike (S) proteins 
by ELISA using anti-IgG or -IgM secondary antibodies for detection (Fig. 1, Extended Data Table 
1 and Extended Data Figs. 2 and 3). Three independent negative controls and the plasma sample 
from participant 21 (COV21) were included for normalization of the area under the curve (AUC). 
Overall, 88% and 66% of the plasma samples tested showed anti-RBD IgG and IgM AUCs that 
were at least 2 standard deviations above the control (Fig. 1 a, b). In contrast, only 40% and 21% 
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of the plasma samples showed anti-S IgG and IgM responses that were at least 2 standard 
deviations above control (Fig. 1 c, d). There was no correlation between IgG or IgM levels and 
age, the timing of sample collection relative to onset of symptoms, and no significant difference 
between cases and contacts (Fig. 1g, h, and Extended Data Figs. 2 a-c and 3 c-i). In contrast, IgG 
binding to RBD and S were directly correlated to duration of symptoms, but IgM binding was not 
(Fig. 1e, f, and Extended Data Fig. 3). Finally, antibody levels to S were similar between genders, 
but females had lower titers of IgG-binding antibodies to RBD than males (Extended Data Fig. 
2d).    
 
To measure the neutralizing activity in convalescent plasmas we used pseudotyped virus assays 
that employed HIV-1-based virions carrying a nanoluc luciferase reporter and the SARS-CoV-2 
spike (pSARS-CoV2-Strunc see Methods, Fig. 2 and Extended Data Fig. 4). The overall level of 
neutralizing activity in the cohort, as measured by the half-maximal neutralizing titer (NT50) was 
generally low, with 18% undetectable and 78% below 1,000 (Fig. 2a, b). The geometric mean NT50 
was 212 (arithmetic mean = 850), and only 2 individuals reached NT50s above 5,000 (Fig. 2a, b, 
Extended Data Table 1). Neutralizing activity correlated with the duration of symptoms and 
symptom severity but did not correlate with the timing of sample collection relative to onset of 
symptoms, age, sex or case/contact status (Fig. 2c, e, f and Extended Data Fig. 5). Notably, levels 
of RBD- and S-binding IgG antibodies correlated strongly with NT50 (Fig. 2d and Extended Data 
Fig. 5e). 
 
To determine the nature of the antibodies elicited by SARS-CoV-2 infection we used flow 
cytometry to isolate individual B lymphocytes with receptors that bound to RBD from the blood 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted May 15, 2020. . https://doi.org/10.1101/2020.05.13.092619doi: bioRxiv preprint 
of 6 individuals including the 2 top neutralizers (Fig. 3). The frequency of antigen-specific B cells, 
identified by their ability to bind to both Phycoerythrin (PE)- and BV711-labeled RBD, ranged 
from 0.07 to 0.005% of circulating B cells in COVID-19 convalescents but they were undetectable 
in controls (Fig.3a and Extended Data Fig.6). We obtained 534 paired IgG heavy and light chain 
(IGH and IGL) sequences by reverse transcription and subsequent PCR from individual RBD-
binding B cells from the 6 convalescent individuals (see Methods). When compared to the human 
antibody repertoire, several IGH and IGL genes were significantly over-represented (Extended 
Data Fig. 7). The average number of V genes nucleotide mutations for IGH and IGL was 4.2 and 
2.8, respectively (Extended Data Fig. 8), which is lower than in antibodies cloned from individuals 
suffering from chronic infections such as Hepatitis B or HIV-1, and similar to antibodies derived 
from primary malaria infection or non-antigen-enriched circulating IgG memory cells6-8 (Wang et 
al, in press, https://www.biorxiv.org/content/10.1101/2020.03.04.976159v1.full). Among other 
antibody features, IGH CDR3 length was indistinguishable from the reported norm and 
hydrophobicity was below average (Extended Data Fig. S8)9.  
 
As is the case with other human pathogens, there were expanded clones of antigen binding B cells 
in all COVID-19 individuals tested (see Methods and Fig. 3b, c). Overall, 32.2% of the recovered 
IGH and IGL sequences were from clonally expanded B cells (range 21.8-57.4% across 
individuals, Fig. 3b). Antibodies that shared specific combinations of IGHV and IGLV genes in 
different individuals comprised 14% of all the clonal sequences (colored pie slices in Fig. 3b, c). 
Remarkably, the amino acid sequences of some antibodies found in different individuals were 
nearly identical. For example, clonal antibodies with IGHV1-58/IGKV3-20 and IGHV3-30-
3/IGKV1-39 found repeatedly in different individuals had amino acid sequence identities of up to 
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99% and 92%. We conclude that the IgG memory response to the SARS-CoV-2 RBD is highly 
enriched in recurrent clonally expanded antibody sequences.      
 
To examine the binding properties of anti-SARS-CoV-2 antibodies, we expressed 34 
representative antibodies, 24 from clones and 10 from singlets found in 3 individuals. ELISA 
assays showed that 94% (32 out of 34) of the antibodies bound to the SARS-CoV-2 RBD with an 
average half-maximal effective concentration (EC50) of 6.6 ng/mL (Fig 4a, b). To determine 
whether these antibodies have neutralizing activity, we tested them against the SARS-CoV2-Strunc 
pseudovirus (Fig. 4c, d and Extended Data Table 3). Among 32 RBD binding antibodies tested, 
we found 20 that neutralized with nanogram per milliliter half-maximal inhibitory concentrations 
(IC50s) ranging from 4.4 to 709 ng/mL (Fig. 4c, d and Extended Data Table 3). Potent neutralizing 
antibodies were found in individuals irrespective of their plasma NT50s. For example, C002 and 
C121 with IC50s of 8.9 and 6.7 ng/mL, respectively, were obtained from individuals COV21 and 
COV107 whose plasma NT50 values were of 5053 and 298 respectively (Fig. 2b and 4). Finally, 
clones of antibodies with shared IGHV and IGLV genes were among the best neutralizers, e.g., 
antibody C002 with IGHV3-30/IGKV1-39 that is shared by the 2 donors with the best plasma 
neutralizing activity (red pie slice in Fig. 3b and Fig. 4). We conclude that even individuals with 
modest plasma neutralizing activity harbor rare IgG memory B cells that produce potent SARS-
CoV-2 neutralizing antibodies.    
 
To determine whether human anti-SARS-CoV-2 monoclonal antibodies with neutralizing activity 
can bind to distinct domains on the RBD we performed bilayer interferometry experiments in 
which a preformed antibody-RBD immune complex was exposed to a second monoclonal. The 
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antibodies tested comprised 2 groups, whereas, C002, and C105 bound to a pre-formed C121-RBD 
complex, C104, C110 and C119 did not (Fig 4e and f). We conclude that like SARS-CoV-110, 
there are at least 2 distinct neutralizing epitopes on the RBD of SARS-CoV-2.           
 
Human monoclonal antibodies with neutralizing activity against pathogens ranging from viruses 
to parasites have been obtained from naturally infected individuals by single cell antibody cloning. 
Several have been shown to be effective in protection and therapy in model organisms and in early 
phase clinical studies, but only one antiviral monoclonal is currently in clinical use11. Antibodies 
are relatively expensive and more difficult to produce than small molecule drugs. However, they 
differ from drugs in that they can engage the host immune system through their constant domains 
that bind to Fc gamma receptors on host immune cells12. These interactions can enhance immunity 
and help clear the pathogen or infected cells, but they can also lead to disease enhancement during 
Dengue13 and possibly coronavirus infections14. This problem has impeded Dengue vaccine 
development but would not interfere with the clinical use of potent neutralizing antibodies that can 
be modified to prevent Fc gamma receptor interactions and remain protective against viral 
pathogens15.  
 
Antibodies are essential elements of most vaccines and will likely be crucial component of an 
effective vaccine against SARS-CoV-216. The observation that plasma neutralizing activity is low 
in most convalescent individuals, but that recurrent anti-SARS-CoV-2 RBD antibodies with potent 
neutralizing activity can be found in individuals with unexceptional plasma neutralizing activity 
suggests that humans are intrinsically capable of generating anti-RBD antibodies that potently 
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neutralize SARS-CoV-2. Thus, vaccines that specifically and efficiently induce antibodies 
targeting the SARS-CoV-2 RBD may be especially effective.    
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Figures 
 
Figure 1. Plasma antibodies against SARS-CoV-2. a-d, Graphs show results of ELISAs 
measuring plasma reactivity to RBD (a, b) and S protein (c, d). Left shows optical density units at 
450 nm (OD, Y axis) and reciprocal plasma dilutions (X axis). Negative control in black; 
individuals 21, 47, and 201 in green, red, and blue lines and arrowheads, respectively. Right shows 
normalized area under the curve (AUC) for controls and each of 68 individuals in the cohort. e, 
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Duration of symptoms (Sx) in days (Y axis) plotted against normalized AUC for IgG binding to 
RBD (X axis) r=0.4107 and p=0.0005. f, Duration of symptoms in days (Y axis) plotted against 
normalized AUC for IgG binding to S (X axis) r=0.2716 and p=0.0251. g, Age (Y axis) plotted 
against normalized AUC for IgG binding to RBD (X axis) r=0.0071 p=9539. The r and p values 
for the correlations in e-g were determined by two-tailed Spearman’s. h, Normalized AUC for IgG 
binding to RBD (Y axis) for all RT-PCR confirmed cases and close contacts in the cohort. 
Horizontal bars indicate median values. Statistical significance was determined using two-tailed 
Mann-Whitney U test (p=0.2591).   
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 Figure 2. Neutralization of SARS-CoV-2 pseudovirus by plasma. a, Graph shows normalized 
relative luminescence values (RLU, Y axis) in cell lysates of 293T-ACE2 cells 48 hours after 
infection with nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing 
concentrations of plasma (X axis) derived from 68 participants (grey, except individuals 21, 47 
and 201 in green, red, and blue lines, bars and arrowheads, respectively) and 3 negative controls 
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(black lines). Standard deviations of duplicates of one representative experiment are shown. b, 
Average half-maximal inhibitory plasma neutralizing titer (NT50) for the 44 of 68 individuals with 
NT50s >200. See also Extended Data Table 1. c, Duration of symptoms in days (Y axis) plotted 
against NT50 (X axis) r=0.5064, p=<0.0001. d, AUC for anti-RBD IgG ELISA (Y axis) plotted 
against NT50 (X axis) r=0.6677, p=<0.0001. e, NT50 (Y axis) for all males and females in the cohort 
p=0.1706. f, NT50 (Y axis) for all cases and contacts in the cohort p=0.2466. Dotted line (NT50=5) 
represents lower limit of detection (LLOD). Samples with undetectable neutralizing titers were 
plotted at LLOD. Correlations in c and d were determined by two-tailed Spearman’s. Horizontal 
bars indicate median values. Statistical significance in e and f was determined using two-tailed 
Mann-Whitney U test.  
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 Figure 3. Anti-SARS-CoV-2 RBD antibodies. a. Representative flow cytometry plots showing 
dual BV711- and PE-RBD binding B cells in control and 6 study individuals (for gating strategy 
see Extended Data Fig. 6). Percentages of antigen specific B cells are indicated. b, Pie charts 
depicting the distribution of antibody sequences from 6 individuals. The number in the inner circle 
indicates the number of sequences analyzed for the individual denoted above the circle. White 
indicates sequences isolated only once, and grey or colored pie slices are proportional to the 
number of clonally related sequences. Red, blue, orange and yellow pie slices indicate clones that 
share the same IGHV and IGLV genes. c, Circos plot shows sequences from all 6 individuals with 
clonal relationships depicted as in b. Interconnecting lines indicate the relationship between 
antibodies that share V and J gene segment sequences at both IGH and IGL. Purple, green and 
gray lines connect related clones, clones and singles, and singles to each other, respectively.  
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 Figure 4. Anti-SARS-CoV-2 RBD antibody reactivity. a, Graph show results of ELISA assays 
measuring monoclonal antibody reactivity to RBD. Left shows optical density units at 450 nm 
(OD, Y axis) and reciprocal dilutions (X axis). Representative experiment. b, Graph shows mean 
EC50s of at least two independent experiments. c, Graph shows normalized relative luminescence 
values (RLU, Y axis) in cell lysates of 293TACE2 cells 48 hours after infection with SARS-CoV-2 
pseudovirus in the presence of increasing concentrations of monoclonal antibodies (X axis). 
Representative experiment. d. IC50s of at least two independent experiments (see Extended Data 
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Table 3). For a and c panels, isotype control antibody in black, C002 blue, C121 red. e, 
Diagrammatic representation of Biolayer Interferometry competition assay. f, Graph shows 
binding of C002 and C105 but not C104, C110, C119 to preformed C121-RBD immune 
complexes.  
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Methods 
Study participants. Study participants were recruited at the Rockefeller University Hospital in 
New York from April 1 through April 17, 2020. Eligible participants were adults aged 18-75 years 
who were either diagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptoms 
of COVID-19 for at least 14 days (cases), or who were close contacts (e.g., household, co-workers, 
members of same religious community) with someone who had been diagnosed with  SARS-CoV-
2 infection by RT-PCR and were free of symptoms suggestive of COVID-19 for at least 14 days 
(contacts). Exclusion criteria included presence of symptoms suggestive of active SARS-CoV-2 
infection, or hemoglobin < 12 g/dL for males and < 11 g/dL for females. 
Study participants were residents of the Greater New York City tri-state region and were enrolled 
sequentially according to eligibility criteria. Participants were first interviewed by phone to collect 
information on their clinical presentation, and subsequently presented to the Rockefeller 
University Hospital for a single blood sample collection.  Participants were asked to rate the 
highest severity of their symptoms on a numeric rating scale ranging from 0 to 10. The score was 
adapted from the pain scale chart, where 0 was the lack of symptoms, 4 were distressing symptoms 
(e.g. fatigue, myalgia, fever, cough, shortness of breath) that interfered with daily living activities, 
7 were disabling symptoms that prevented the performance of daily living activities, and 10 was 
unimaginable/unspeakable discomfort (in this case, distress due to shortness of breath). All 
participants provided written informed consent before participation in the study and the study was 
conducted in accordance with Good Clinical Practice.  
 
Blood samples processing and storage. Peripheral Blood Mononuclear Cells (PBMCs) were 
obtained by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and 
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DMSO. Plasma and serum samples were aliquoted and stored at -20C or less. Prior to experiments, 
aliquots of plasma samples were heat-inactivated (56C for 1 hour) and then stored at 4C. 
 
Cloning, expression and purification of recombinant SARS-CoV-2 proteins. Codon-
optimized nucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues 16-1206) and 
receptor binding domain (RBD; residues 331-524) were synthesized and subcloned into the 
mammalian expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies based 
on an early SARS-CoV-2 sequence isolate (GenBank MN985325.1). The SARS-CoV-2 RBD 
construct included an N-terminal human IL-2 signal peptide and dual C-terminal tags ((GGGGS)2-
HHHHHHHH (octa-histidine), and GLNDIFEAQKIEWHE (AviTag)). The SARS-CoV-2 S 
ectodomain was modified as previously described 4. Briefly, the S ectodomain construct included 
an N-terminal mu-phosphatase signal peptide, 2P stabilizing mutations (K986P and V987P), 
mutations to remove the S1/S2 furin cleavage site (682RRAR685 to GSAS), a C-terminal extension 
(IKGSG-RENLYFQG (TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL 
(foldon trimerization motif), G-HHHHHHHH (octa-histidine tag), and GLNDIFEAQKIEWHE 
(AviTag)). The SARS-CoV-2 S 2P ectodomain and RBD constructs were produced by transient 
transfection of 500 mL of Expi293 cells (Thermo Fisher) and purified from clarified transfected 
cell supernatants four days post-transfection using Ni2+-NTA affinity chromatography (GE Life 
Sciences). Affinity-purified proteins were concentrated and further purified by size-exclusion 
chromatography (SEC) using a Superdex200 16/60 column (GE Life Sciences) running in 1x TBS 
(20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.02% NaN3). Peak fractions were analyzed by SDS- 
PAGE, and fractions corresponding to soluble S 2P trimers or monomeric RBD proteins were 
pooled and stored at 4˚C.  
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 ELISAs. ELISAs to evaluate antibodies binding to SARS-CoV-2 RBD and trimeric spike proteins 
were performed by coating of high binding 96 half well plates (Corning #3690) with 50 µL per 
well of a 1µg/mL protein solution in PBS overnight at 4°C. Plates were washed 6 times with 
washing buffer (1xPBS with 0.05% Tween 20 (Sigma-Aldrich)) and incubated with 170 µL per 
well blocking buffer (1xPBS with 2% BSA and 0.05% Tween20 (Sigma)) for 1 hour at room 
temperature (RT). Immediately after blocking, monoclonal antibodies or plasma samples were 
added in PBS and incubated for 1 hr at RT. Plasma samples were assayed at a 1:200 starting 
dilution and seven additional 3-fold serial dilutions. Monoclonal antibodies were tested at 10µg/ml 
starting concentration and 10 additional 4-fold serial dilutions. Plates were washed 6 times with 
washing buffer and then incubated with anti-human IgG or IgM secondary antibody conjugated to 
horseradish peroxidase (HRP) (Jackson Laboratories) in blocking buffer at a 1:5000 dilution. 
Plates were developed by addition of the HRP substrate, TMB (ThermoFisher) for 10 minutes, 
then the developing reaction was stopped by adding 50µl 1M H2SO4 and absorbance was measured 
at 450nm with an ELISA microplate reader (FluoStar Omega, BMG Labtech). For plasma and 
monoclonal antibodies, a positive control plasma sample (COV21) was added in duplicate to every 
individual assay plate for normalization. The positive sample optical density measured was set to 
100 and AUC measurements were normalized according to the factor defined for each plate’s 
positive control. For monoclonal antibodies, the half-maximal effective concentration (EC50) was 
determined using 4-parameter nonlinear regression (GraphPad Prism). 
 
293TACE2 cells. For constitutive expression of ACE2 in 293T cells, a cDNA encoding ACE2, 
carrying two inactivating mutations in the catalytic site (H374N & H378N), was inserted into CSIB 
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3’ to the SFFV promoter18. 293TACE2 cells were generated by transduction with CSIB based virus 
followed by selection with 5 µg/ml Blasticidin.  
 
SARS-CoV-2 pseudotyped reporter virus. A plasmid expressing a C-terminally truncated 
SARS-CoV-2 S protein (pSARS-CoV2-Strunc) was generated by insertion of a human-codon 
optimized cDNA encoding SARS-CoV-2 S lacking the C-terminal 19 codons (Geneart) into 
pCR3.1. An env-inactivated HIV-1 reporter construct (pNL4-3DEnv-NanoLuc) was generated 
from pNL4-3 19 by introducing a 940 bp deletion 3’ to the vpu stop-codon, resulting in a frameshift 
in env. The human codon-optimized NanoLuc Luciferase reporter gene (Nluc, Promega) was 
inserted in place of nucleotides 1-100 of the nef-gene. To generate pseudotyped viral stocks, 293T 
cells were transfected with pNL4-3DEnv-NanoLuc and pSARS-CoV2-Strunc using 
polyethyleneimine. Co-transfection of pNL4-3DEnv-NanoLuc and pSARS-CoV2-Strunc leads to 
production of HIV-1-based virions carrying the SARS-CoV-2 Spike protein on the surface. Eight 
hours after transfection, cells were washed twice with PBS and fresh media was added. 
Supernatants containing virions were harvested 48 hours post transfection, filtered and stored at -
80 °C. Infectivity of virions was determined by titration on 293TACE2 cells.  
 
Pseudotyped virus neutralization assay. Five-fold serially diluted plasma from COVID-19 
convalescent individuals and healthy donors was incubated with the SARS-CoV-2 pseudotyped 
virus for 1 hour at 37 degrees. The mixture was subsequently incubated with 293TACE2 cells for 48 
hours after which cells were washed twice with PBS and lysed with Luciferase Cell Culture Lysis 
5x reagent (Promega). NanoLuc Luciferase activity in lysates was measured using the Nano-Glo 
Luciferase Assay System (Promega). Relative luminescence units obtained were normalized to 
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those derived from cells infected with SARS-CoV-2 pseudotyped virus in the absence of plasma. 
The half-maximal inhibitory concentration for plasma (NT50) or monoclonal antibodies (IC50) was 
determined using 4-parameter nonlinear regression (GraphPad Prism). For experiments testing 
antibody combinations, equal amounts of each antibody were added at the same concentration of 
when tested alone (for example, if antibody A and B alone are tested at 10ng/mL, the combination 
is 10ng/mL of each, resulting in 20ng/mL total concentration and this is the concentration that is 
plotted). 
 
Biotinylation of viral protein for use in flow cytometry. Purified and Avi-tagged SARS-CoV-2 
RBD was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer’s 
instructions (Avidity). Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-
NHS-LC-Biotinylation kit according to the manufacturer’s instructions (Thermo Scientific). 
Biotinylated Ovalbumin was conjugated to streptavidin Alexa Fluor 647 (Biolegend, 405237) and 
RBD to streptavidin PE (BD biosciences, 554061) and streptavidin BV711 (BD biosciences, 
563262) respectively 20. 
 
Single cell sorting by flow cytometry. PBMCs were enriched for B cells by negative selection 
using a pan B cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-
101-638). The enriched B cells were incubated in FACS buffer (1 X Phosphate-buffered Saline 
(PBS), 2% calf serum, 1 mM EDTA) with the following anti-human antibodies: anti-CD20-PECy7 
(BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-
eFluro 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluro 780 (Invitrogen, 47-0168-41), anti-
CD14-APC-eFluro 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105), 
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and fluorophore-labeled RBD and Ovalbumin for 30 minutes on ice 20. Single CD3-CD8-CD16-
CD20+Ova-RBD-PE+RBD-APC+ B cells were sorted into individual wells of a 96-well plates 
containing 4 μl of lysis buffer (0.5 X PBS, 10mM DTT, 3000 units/mL RNasin Ribonuclease 
Inhibitors (Promega, N2615) per well using a FACS Aria III (Becton Dickinson). The sorted cells 
were frozen on dry ice, and then stored at −80°C or immediately used for subsequent RNA reverse 
transcription.  
 
Antibody sequencing, cloning and expression. Antibodies were identified and sequenced as 
described previously 21-23. Briefly, RNA from single cells was reverse-transcribed (SuperScript III 
Reverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at -20°C or used for 
subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger 
sequencing 21. Amplicons from the first PCR reaction were used as templates for Sequence- and 
Ligation-Independent Cloning (SLIC) into antibody expression vectors. Recombinant monoclonal 
antibodies were produced and purified as previously described 24.  
 
Biolayer interferometry. 
BLI assays were performed on the Octet Red instrument (ForteBio) at 30 °C with shaking at 1,000 
r.p.m. Epitope binding assays were performed with protein A biosensor (ForteBio 18-5010), 
following the manufacture protocol “classical sandwich assay”. (1) Sensor check: sensors 
immersed 30sec in buffer alone (buffer ForteBio 18-1105). (2) Capture 1st Ab: sensors immersed 
10min with Ab1 at 40µg/mL. (3) Baseline: sensors immersed 30sec in buffer alone. (4) Blocking: 
sensors immersed 5min with IgG isotype control at 50µg/mL. (6) Antigen association: sensors 
immersed 5min with RBD at 100µg/mL. (7) Baseline: sensors immersed 30sec in buffer alone. (8) 
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Association Ab2: sensors immersed 5min with Ab2 at 40µg/mL. Curve fitting was performed 
using the Data analysis software (ForteBio). 
  
Computational analyses of antibody sequences. Antibody sequences were trimmed based on 
quality and annotated using Igblastn v1.14.0 25 with IMGT domain delineation system. Annotation 
was performed systematically using Change-O toolkit v.0.4.5 26.  Heavy and light chains derived 
from the same cell were paired, and clonotypes were assigned based on their V and J genes using 
in-house R and Perl scripts (Fig. 3b, c).  
The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 
was compared to Sequence Read Archive SRP010970 17. The V(D)J assignments were done using 
IMGT/High V-Quest and the frequencies of heavy and light chain V genes were calculated for 14 
and 13 individuals, respectively, using sequences with unique CDR3s. The two-tailed t test with 
unequal variances was used to determine statistical significance (Extended Data Figure 7). 
Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl 
scripts. To calculate the GRAVY scores of hydrophobicity 27 we used Guy H.R. Hydrophobicity 
scale based on free energy of transfer (kcal/mole)28 implemented by the R package Peptides 
available in the Comprehensive R Archive Network repository (https://journal.r-
project.org/archive/2015/RJ-2015-001/RJ-2015-001.pdf). We used 534 heavy chain CDR3 amino 
acid sequences from this study and 22,654,256 IGH CDR3 sequences from the public database of 
memory B-cell receptor sequences 29. The Shapiro-Wilk test was used to determine whether the 
GRAVY scores are normally distributed. The GRAVY scores from all 534 IGH CDR3 amino acid 
sequences from this study were used to perform the test and 5000 GRAVY scores of the sequences 
from the public database were randomly selected. The Shapiro-Wilk p-values were 6.896 x 10-3 
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and 2.217 x 10-6 for sequences from this study and the public database, respectively, indicating the 
data are not normally distributed. Therefore, we used the Wilcoxon non-parametric test to compare 
the samples, which indicated a difference in hydrophobicity distribution (p = 5 x 10-6; Extended 
Data Figure 7).  
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Extended Data Figures 
 
Extended Data Figure 1. Clinical correlates. a, Duration of symptoms in days (Y axis) for all 
males and females in the cohort p=0.3681. b, Time between symptom onset and plasma collection 
(Y axis) for all males and females in the cohort p=0.7004. c, Subjective symptom severity on a 
scale of 0-10 (Y axis) for all males and females in the cohort p=0.1603. d, Duration of symptoms 
in days (Y axis) for all cases and contacts p=0.4755. e, Time between symptom onset and plasma 
collection in days (Y axis) for all cases and contacts p=0.7465. f, Symptom severity (Y axis) for 
all cases and contacts in the cohort p=0.6428.  Horizontal bars indicate median values. Statistical 
significance was determined using two-tailed Mann-Whitney U test.  
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 Extended Data Figure 2. Clinical correlates of plasma antibody titers. a, AUC for IgM anti-
RBD (Y axis) for all cases and contacts in the cohort p=0.2795. b, AUC for IgG anti-S (Y axis) 
for all cases and contacts in the cohort p=0.5191. c, AUC for IgM anti-S (Y axis) for all cases and 
contacts in the cohort p=0.7512. d, AUC for IgG anti-RBD (Y axis) for all males and females in 
the cohort p=0.0466. e, AUC for IgM anti-RBD (Y axis) for all males and females in the cohort 
p=0.0466. f, AUC for IgG anti-S (Y axis) for all males and females in the cohort p=0.5425. g, 
AUC for IgM anti-S (Y axis) for all males and females in the cohort p=0.5263. Horizontal bars 
indicate median values. Statistical significance was determined using two-tailed Mann-Whitney U 
test.  
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 Extended Data Figure 3. Additional clinical correlates of plasma antibody titers. a, Duration 
of symptoms in days (Y axis) plotted against AUC for IgM anti-RBD (X axis) r=0.2346, p=0.0541. 
b, Duration of symptoms in days (Y axis) plotted against AUC for IgM anti-S (X axis) r=0.2119, 
p=0.0828. c, Age (Y axis) plotted against AUC for IgM anti-RBD (X axis) r=0.0919 p=0.4559. d, 
Age (Y axis) plotted against AUC for IgG anti-S (X axis) r=0.0130 p=0.9160. e, Age (Y axis) 
plotted against AUC for IgM anti-S (X axis) r=0.1319 p=0.2835. f, Time between symptom onset 
and plasma collection in days (Y axis) plotted against AUC for IgG anti-RBD (X axis) r=0.1366 
p=0.2703. g, Time between symptom onset and plasma collection in days (Y axis) plotted against 
AUC for IgM anti-RBD (X axis) r=0.0549 p=0.6590. h, Time between symptom onset and plasma 
collection in days (Y axis) plotted against AUC for IgG anti-S (X axis) r=0.0565 p=0.6500. i, Time 
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between symptom onset and plasma collection in days (Y axis) plotted against AUC for IgM anti-
S (X axis) r=0.1573 p=0.2036. j, Severity of symptoms (Y axis) plotted against AUC for IgG anti-
RBD (X axis) r=0.4316 p=0.0002. k, Severity of symptoms (Y axis) plotted against AUC for IgM 
anti-RBD (X axis) r=0.2694 p=0.0263. l, Severity of symptoms (Y axis) plotted against AUC for 
IgG anti-S (X axis) r=0.1952 p=0.1106. m, Severity of symptoms (Y axis) plotted against AUC 
for IgM anti-S (X axis) r=0.1714 p=0.1622. All correlations were analyzed by two-tailed 
Spearman’s.  
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 Extended Data Figure 4. Diagrammatic representation of the SARS-CoV2-Strunc luciferase 
assay. a, Co-transfection of pNL4-3ΔEnv-NanoLuc and pSARS-CoV-2 spike vectors into 293T 
cells leads to production of SARS-CoV-2 Spike-pseudotyped HIV-1 particles (SARS-CoV-2 
pseudovirus) carrying the NanoLuc gene. b, SARS-CoV-2 pseudovirus is incubated for 1 h at 37 
°C with plasma dilutions from COVID-19 patients or monoclonal antibodies. The virus-antibody 
mixture is used to infect ACE2-expressing 293T cells, which will express NanoLuc Luciferase 
upon infection. c, Relative luminescence units (RLU) reads from lysates of ACE2-expressing 293T 
cells infected with increasing amounts of SARS-CoV-2 pseudovirus (SARS-CoV-2 S) or non-
pseudotyped control virus (w/o S).  
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted May 15, 2020. . https://doi.org/10.1101/2020.05.13.092619doi: bioRxiv preprint 
 Extended Data Figure 5. Clinical correlates of neutralization. a, Time between symptom onset 
and plasma collection in days (Y axis) plotted against NT50 (X axis) r=0.0834, p=0.5024. b, 
Symptom severity (Y axis) plotted against NT50 (X axis) r=0.5075, p=<0.0001. c, Age (Y axis) 
plotted against NT50 (X axis) r=0.0611, p=0.6204. d, Anti-RBD IgM AUC (Y axis) plotted against 
NT50 (X axis) r=0.4457, p=0.0001. e, Anti-S IgG AUC (Y axis) plotted against NT50 (X axis) 
r=0.6155, p=0.0001. f, Anti-S IgM AUC (Y axis) plotted against NT50 (X axis) r=0.3567, 
p=0.0028. All correlations were analyzed by two-tailed Spearman’s. Dotted line (NT50=5) 
represents lower limit of detection (LLOD) of pseudovirus neutralization assay. Samples with 
undetectable neutralizing titers were plotted at LLOD.  
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 Extended Data Figure 6. Flow cytometry. Gating strategy used for cell sorting. Gating was on 
singlets that were CD20+ and CD3-CD8-CD16-Ova-. Sorted cells were RBD-PE+ and RBD-
BV711+.   
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 Extended Data Figure 7. Frequency distributions of human V genes. The two-tailed t test with 
unequal variance was used to compare the frequency distributions of human V genes of anti-
SARS-CoV-2 antibodies from this study to Sequence Read Archive SRP01097017.  
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 Extended Data Figure 8. Analysis of antibody somatic hypermutation and CDR3 length. a, 
For each individual, the number of somatic nucleotide mutations (Y axis) at the IGVH and IGVL 
are shown on the left panel, and the amino acid length of the CDR3s (Y axis) are shown on the 
right panel. The horizontal bar indicated the mean. b, same as in a but for all antibodies combined. 
c, Distribution of the hydrophobicity GRAVY scores at the IGH CDR3 in antibody sequences 
from this study compared to a public database (see Methods). 
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